Patients with recalcitrant hidradenitis suppurativa may respond to off-label golimumab

More than half of patients with treatment-resistant hidradenitis suppurativa achieved a 55% improvement in their disease after initiating golimumab, a tumor necrosis factor inhibitor, according to a study published in JAMA Dermatology. Tumor necrosis factor (TNF) inhibitors are often used to treat HS; however, clinicians have only one FDA-approved TNF inhibitor for this indication, adalimumab